While the Gray Market Premium (GMP) reflects the strong interest of investors, it remains a speculative indicator and may change quickly before listed.
Rs. The 3,395 crore IPO was the offer for sale (OFS) and closed on July 16. It saw strong demand with overall subscription 67.42 times. Eligible institutional buyers (QIB) were subscribed 192.80 times in the segment, non-institutional investors (NII) 44.70 times, and retail part 5.98 times.
The price was priced at a band of Rs 540-570 per share, with a size of at least 26 shares. Stock will list on both NSE and BSE.
About anthum bioscience
Established in 2006, Anthum Bioscience operates in a special part of the pharma value chain, providing drug search, development and production services from the end to end. It is one of the few Indian CRDMOs with unified capabilities in both small molecules (chemical based) and large atoms (biologics).
Its differential fee-for-service (FFS) model has enabled it to meet small and medium-sized biotech companies globally, making it a larger part of its client base. Since the beginning, the company has served more than 675 customers and completed more than 8,000 projects.
In FY 25, Anthem reported strong financial affairs with EBITD margins of 36.8% and a return on a net worth (RonW) of 20.8%. As of March 2025, the company’s net cost is Rs 2,410 crore.
Its features are CGMP-compatible and are recognized by global regulatory organizations such as USFDA, Envisa, TGA and PMDA. The company is currently expanding its fermentation and synthesis to meet the growing demand for complex organisms and specialty components.
JM Financial is the lead manager running an Anthem Bioscience IPO, while KFIN technologies are registrars for this issue.
(Disclaimer: The views given by recommendations, suggestions, opinions and experts are their own. This does not represent the views of the economic time)
(Now you can subscribe to our Etmarkets WhatsApp channel)
